WILLIAM KORNEGAY: Open Payments
NPI 1366160277 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,032 in 131 payments from 13 companies in 2025. Trend: 2023 $1,844 · 2024 $1,877 · 2025 $3,032
Food & beverage: $3,008Education: $24
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 28 | $649 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $533 |
| Neurocrine BioSciences, Inc. | 16 | $352 |
| ABBVIE INC. | 18 | $256 |
| Alkermes, Inc. | 11 | $249 |
| Janssen Pharmaceuticals, Inc | 7 | $229 |
| Otsuka America Pharmaceutical, Inc. | 7 | $208 |
| Vanda Pharmaceuticals Inc. | 9 | $170 |
| Lundbeck LLC | 6 | $158 |
| Teva Pharmaceuticals USA, Inc. | 5 | $105 |
Products named: COBENFY, CAPLYTA, INGREZZA, VRAYLAR, REXULTI, INVEGA SUSTENNA, FANAPT, ARISTADA.
Industry payments across CT — which companies pay providers there.
